Richard Cathomas
A5050931392- Prostate Cancer Treatment and Research
- Testicular diseases and treatments
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Urinary and Genital Oncology Studies
- Urologic and reproductive health conditions
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Sarcoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Bone health and treatments
- Prostate Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Sexual Differentiation and Disorders
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Chronic Lymphocytic Leukemia Research
- Management of metastatic bone disease
Kantonsspital Graubünden
2016-2025
University of Zurich
2018-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
Swiss Group For Clinical Cancer Research
2013-2023
National Cancer Registration Service
2021
University Hospital of Bern
2018-2019
Kantonsspital St. Gallen
2012-2018
Düsseldorf University Hospital
2018
University of Bern
2018
Heinrich Heine University Düsseldorf
2018
BackgroundLong-term hormone therapy has been the standard of care for advanced prostate cancer since 1940s. STAMPEDE is a randomised controlled trial using multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent who are starting first-line long-term therapy. We report primary survival results three research comparisons testing addition zoledronic acid, docetaxel, their combination to versus alone.MethodsStandard was at least 2 years;...
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings 2003 (Essen, Germany) 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. consensus diagnosis treatment germ-cell cancer: a report Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; S, Beyer J, R second meeting group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; II. 497-513]. A panel 56 60...
Previous studies suggested that serum levels of microRNA (miR)-371a-3p (so-called M371 test) have a much higher sensitivity and specificity than the classic markers testicular germ cell tumors (GCTs) are applicable toward both seminoma nonseminoma. We sought to confirm usefulness this test as novel biomarker for GCT.
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held 3-5 November 2016 in Paris, France. included a multidisciplinary panel of 36 leading experts the diagnosis and treatment (34 members attended conference; an additional two [CB K-PD] participated all preparatory work subsequent manuscript development). aim to develop detailed recommendations topics relating that are not covered detail current ESMO Clinical Practice Guidelines (CPGs) where...
For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% the SAKK 16/00 trial is an accepted standard care. We investigated additional benefit perioperative treatment durvalumab.Neoadjuvant consisted three cycles 100 mg/m2 85 once every 3 weeks two doses durvalumab 750 mg 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end...
Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects promoting immune responses. BI1361849 (CV9202) is an active immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, MUC-1), intended to induce targeted responses.We describe a phase Ib clinical trial evaluating treatment with combined radiation in 26...
The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in management germ-cell tumors, but relies on data only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this database from large international consortium.Data 2,451 men metastatic cisplatin- etoposide-based first-line chemotherapy 1990 2013 were collected 30 institutions or collaborative groups Australia, Europe, North America. Clinical trial registry...
BackgroundAbiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed evaluate long-term and test whether combining abiraterone survival.MethodsWe analysed two open-label, randomised, controlled, phase 3 trials STAMPEDE platform protocol, no overlapping controls, conducted 117 sites in UK Switzerland. Eligible (no age restriction) had...
Radiolabeled somatostatin (sst) receptor agonists are integral to the diagnosis of gastroenteropancreatic neuroendocrine tumors (NETs), but detection rates, especially liver metastases, remain limited even with PET/CT. <sup>68</sup>Ga-OPS202 (<sup>68</sup>Ga-NODAGA-JR11; NODAGA = 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid and JR11 Cpa-c(dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys)-dTyr-NH<sub>2</sub>)), a novel radiolabeled sst antagonist high affinity for sst<sub>2</sub> receptor, has...
Craig R. Nichols, Virginia Mason Medical Center, Seattle, WA Bruce Roth, Washington University School of Medicine, St Louis, MO Peter Albers, Hospital Heinrich-Heine, Dusseldorf, Germany Lawrence H. Einhorn and Richard Foster, Melvin Bren Simon Cancer Indiana Indianapolis, IN Siamak Daneshmand, Norris Comprehensive Southern California, Los Angeles, CA Michael Jewett Padraig Warde, Princess Margaret Hospital, Toronto, Ontario, Canada Christopher J. Sweeney Clair Beard, Dana-Farber Institute,...
5001 Background: STAMPEDE is a randomised controlled trial using novel multi-arm multi-stage design. It recruits men (pts) with high-risk locally advanced or metastatic prostate cancer (PCa) starting long-term hormone therapy (HT) for the first time. The initially assessed adding 1 2 of 3 treatment approaches to standard care (SOC). We report primary survival results research comparisons that recruited through all their intermediate analyses: docetaxel (D), zoledronic acid (ZA) & combination...
Advanced non-small cell lung cancer (NSCLC) represents a significant unmet medical need. Despite advances with targeted therapies in small subset of patients, fewer than 20% patients survive for more two years after diagnosis. Cancer vaccines are promising therapeutic approach that offers the potential durable responses through engagement patient's own immune system. CV9202 is self-adjuvanting mRNA vaccine targets six antigens commonly expressed NSCLC (NY-ESO-1, MAGEC1, MAGEC2, 5 T4,...
Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules combination liposomal doxorubicin (PLD) advanced solid tumours (NCT00819221). Patients received 28-day cycles of olaparib, continuously (days 1–28) or intermittently 1–7), plus PLD (40 mg m−2, day 1); seven dose cohorts (50–400 bid) were explored to determine the recommended dose. Assessments...